natgillin/translations-raw huggingface dataset:
Cetrotide has not been investigated in patients with hepatic disease. 
Zdravila Cetrotide niso preučili pri bolnicah z jetrno boleznijo.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 0.25 mg cetrorelix (as acetate). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena viala vsebuje 0,25 mg cetroreliksa (v obliki cetroreliksijevega acetata).
Cetrotide has not been investigated in patients with kidney disease. 
Zdravila Cetrotide niso preučili pri bolnicah z ledvično boleznijo.
Cetrotide 0.25 mg powder and solvent for solution for injection Cetrorelix 
Cetrotide 0,25 mg prašek in vehikel za raztopino za injiciranje cetroreliks
7 powder vials with 0.25 mg cetrorelix. 
7 vial praška z 0,25 mg cetroreliksa.
7 pre-filled syringes with 1 mL of solvent. 
7 napolnjenih injekcijskih brizg z 1 ml vehikla.
Immune system disorders 
Bolezni imunskega sistema Občasni:
PHARMACEUTICAL FORM Powder and solvent for solution for injection. 
Zdravilo Cetrotide je prašek in vehikel za raztopino za injiciranje.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Cetrotide 0.25 mg powder for solution for injection cetrorelix 
IME ZDRAVILA IN POT(I) UPORABE Cetrotide 0,25 mg prašek za raztopino za injiciranje cetroreliks subkutana uporaba
Uncommon (may affect up to 1 in 100 women): 
Občasni (pojavijo se lahko pri največ 1 od 100 žensk):
What Cetrotide is 
Kaj je zdravilo Cetrotide
Elderly There is no relevant use of Cetrotide in the geriatric population. 
Starejši bolniki Zdravilo Cetrotide ni namenjeno za uporabo pri starejši populaciji.
Nervous system disorders 
Bolezni živčevja Občasni:
2 ml vials (Type I glass) with a stopper (bromobutyl rubber) and flip-off aluminium cap. 1 vial contains 0.25 mg cetrorelix. 
2-ml viale (steklo tipa I) z zamaškom (bromobutilna guma) in snemno aluminijasto zaporko.
This event is common (may affect up to 1 in 10 women). 
Ta pojav je pogost (pojavi se lahko pri največ 1 od 10 žensk).
At a dose of 0.25 mg per injection repeated injections every 24 hours will maintain the effect of cetrorelix. 
Učinek cetroreliksa se vzdržuje z injiciranjem odmerka 0,25 mg, vsakih 24 ur.
Posology 
Vehikel
Reproductive system and breast disorders 
Motnje reprodukcije in dojk Pogosti:
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Solvent for Cetrotide 0.25 mg 
IME ZDRAVILA IN POT(I) UPORABE vehikel za zdravilo Cetrotide 0,25 mg voda za injekcije
How to store Cetrotide 
Shranjevanje zdravila Cetrotide
1 pre-filled syringe with 1 mL of solvent. 
1 napolnjena injekcijska brizga z 1 ml vehikla.
This is uncommon (may affect up to 1 in 100 women). 
To se zgodi občasno (pojavijo se lahko pri največ 1 od 100 žensk).
This event is uncommon (may affect up to 1 in 100 women). 
Ta pojav je občasen (pojavi se lahko pri največ 1 od 100 žensk).
Solvent 
navzea
STATEMENT OF ACTIVE SUBSTANCE(S) Each vial with powder contains 0.25 mg cetrorelix (as acetate). 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena viala s praškom vsebuje 0,25 mg cetroreliksa (v obliki cetroreliksijevega acetata).
General disorders and administration site conditions Common: 
hud OHSS (III. stopnje po SZO) Splošne težave in spremembe na mestu aplikacije Pogosti:
• Gently pull back the plunger of the syringe. 
• Bat brizge nežno povlecite nazaj.
What Cetrotide contains - The active substance is cetrorelix. 
• Učinkovina je cetroreliks.
NAME OF THE MEDICINAL PRODUCT Cetrotide 0.25 mg powder and solvent for solution for injection 
Cetrotide 0,25 mg prašek in vehikel za raztopino za injiciranje
• Unwrap the needle with the grey mark on it. Screw the grey needle onto the syringe and remove the cap from the grey needle. 
Sivo iglo privijte na brizgo in odstranite zaporko z igle.
Uncommon: Headache 
glavobol Bolezni prebavil: Občasni:
In the future, if the animals are exposed to these infections, the immune system will be able to respond more quickly. 
Če so živali kasneje izpostavljene tem okužbam, se lahko imunski sistem nanje hitreje odzove.
Responses in puppies were lower than in adult dogs in some cases, because of antibodies inherited from their mothers. 
Odzivi pri pasjih mladičih so bili v določenih primerih slabši kot pri odraslih psih, kar je posledica protiteles, ki so jih podedovali od mater.
The percentage of dogs with protective levels of antibodies for parvovirus ranged from 73 to 100%, for parainfluenza virus 73 to 97% and for leptospira 59 to 96%. 
Zaščitne ravni protiteles proti parvovirusu je razvilo od 73 do 100 % psov, proti virusu parainfluence od 73 do 97 % psov in proti leptospiri od 59 do 96 % psov.
In situations where puppies are expected to inherit very high antibody levels from the bitch, the vaccination protocol should be planned accordingly. 
Kadar je mogoče pričakovati, da bodo mladiči od psice podedovali zelo visoke ravni protiteles, je treba načrtovani protokol cepljenja ustrezno prilagoditi.
The effectiveness of Versican Plus DHPPi/L4 was initially investigated in a field study involving 129 dogs. 
Učinkovitost cepiva Versican Plus DHPPi/L4 so najprej raziskali v terenski študiji, v katero so vključili 129 psov.
The dogs were either vaccinated twice with a three to four week interval or they received a single annual booster vaccination. 
Psi so bili bodisi cepljeni dvakrat v razmiku od treh do štirih tednov bodisi so prejeli enkraten letni obnovitveni odmerek cepiva.
• leptospirosis, a bacterial disease that may be transmitted via infected urine and results in bleeding, 
• leptospirozo, tj. bakterijsko boleznijo, ki se lahko prenaša z okuženim urinom in povzroči krvavitve,
The European Commission granted a marketing authorisation valid throughout the European Union, for Versican Plus DHPPi/L4 on 7 May 2014. 
Evropska komisija je dovoljenje za promet z zdravilom Versican Plus DHPPi/L4, veljavno po vsej Evropski uniji, izdala 7. maja 2014.
• canine adenovirus type 1, which causes an acute liver infection that may produce signs of jaundice (yellowing of the skin and eyes); 
• pasjim adenovirusom tipa 1, ki povzroča akutno okužbo jeter, pri kateri se lahko pojavijo znaki zlatenice (porumenelost kože in oči);
The vaccine is given to puppies from six weeks of age as an injection, under the skin, repeated three to four weeks later. 
Cepivo se daje pasjim mladičem, starejšim od šest tednov, z injiciranjem v podkožje, cepljenje pa je treba ponoviti tri do štiri tedne kasneje.
The most common side effect (seen in more than 1 in 100 dogs) with Versican Plus DHPPi/L4 is a shortlived swelling of up to 5 cm which may occur at the injection site after vaccination. 
Najpogostejši neželeni učinek cepiva Versican Plus DHPPi/L4 (opažen pri več kot 1 psu od 100) je kratkotrajna oteklina v velikosti do 5 cm, ki se lahko po cepljenju pojavi na mestu injiciranja.
• canine distemper, an infectious disease which is sometimes called ‘hard pad' since dogs can develop thickening of the skin on the foot pads, as well as runny nose, cough, fever, vomiting, diarrhoea, excessive salivation and in some cases fits; 
• pasjo kugo, tj. infekcijsko boleznijo, ki jo včasih imenujemo tudi bolezen trdih blazinic, saj se lahko pri psih pojavi odebeljena koža na blazinicah na šapah, poleg tega pa tudi izcedek iz smrčka, kašelj, povišana telesna temperatura, bruhanje, driska, čezmerno slinjenje ter v nekaterih primerih krči;
When Versican Plus DHPPi/L4 is given to dogs, the animals' immune system recognises the viruses and bacteria as ‘foreign' and makes antibodies against them. 
Ko psi prejmejo cepivo Versican Plus DHPPi/L4, imunski sistem živali viruse in bakterije prepozna kot „tujke“ ter začne proti njim tvoriti protitelesa.
Versican Plus DHPPi/L4 is used to protect dogs against: 
Zdravilo Versican Plus DHPPi/L4 se uporablja za zaščito psov pred:
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Versican Plus DHPPi/L4 exceed the risks for the approved indications and recommended that Versican Plus DHPPi/L4 be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Versican Plus DHPPi/L4 večje od z njim povezanih tveganj, kadar se zdravilo uporablja za odobrene indikacije, in priporočil, da se zanj izda dovoljenje za promet.
Versican Plus DHPPi/L4 is a veterinary vaccine that contains live attenuated (weakened) canine distemper virus, canine adenovirus type 2, canine parvovirus type 2b and canine parainfluenza virus type 2 as well as inactivated (killed) strains of Leptospira bacteria. 
Zdravilo Versican Plus DHPPi/L4 je cepivo za uporabo v veterinarski medicini, ki vsebuje živ atenuiran (oslabljen) virus pasje kuge, pasji adenovirus tipa 2, pasji parvovirus tipa 2b in virus pasje parainfluence tipa 2 ter inaktivirane (uničene) seve bakterij Leptospira.
• canine parainfluenza virus and canine adenovirus type 2, which cause kennel cough; 
• virusom pasje parainfluence in pasjim adenovirusom tipa 2, ki povzročata kužni kašelj;
In these studies dogs were vaccinated twice with a three week interval and were challenged with canine distemper virus, canine adenovirus and canine parvovirus three years after the second vaccination. 
V teh študijah so bili psi cepljeni dvakrat v razmiku treh tednov, zatem pa so bili tri leta po drugem cepljenju izpostavljeni virusu pasje kuge, pasjemu adenovirusu in pasjemu parvovirusu.
The field study showed that vaccination with Versican Plus DHPPi/L4 resulted in levels of antibodies that were sufficient to protect against canine distemper virus and canine adenovirus in all dogs. 
Terenska študija je pokazala, da so bile po cepljenju s cepivom Versican Plus DHPPi/L4 ravni protiteles pri vseh psih dovolj visoke za zaščito pred virusom pasje kuge in pasjim adenovirusom.
Annual revaccination is required for protection against parainfluenza virus and leptospirosis. 
Za zaščito pred virusom parainfluence in leptospirozo je ponovno cepljenje potrebno vsako leto.
This will help protect them against distemper, adenovirus liver infection, parvovirosis, kennel cough and leptospirosis. 
To pomaga zaščititi pse pred kugo, okužbo jeter z adenovirusom, parvovirozo, kužnim kašljem in leptospirozo.
Versican Plus DHPPi/L4 contains an adjuvant (aluminium hydroxide) to enhance the immune response. 
Cepivo Versican Plus DHPPi/L4 vsebuje adjuvans (aluminijev hidroksid), ki spodbuja imunski odziv.
Versican Plus DHPPi/L4 is a vaccine. 
Zdravilo Versican Plus DHPPi/L4 je cepivo.
Canine distemper, canine adenovirus, canine parvovirosis, canine parainfluenza virus (live attenuated) and canine leptospirosis (inactivated) vaccine 
cepivo proti pasji kugi, pasjemu adenovirusu, pasji parvovirozi, virusu pasje parainfluence (živo, atenuirano) in pasji leptospirozi (inaktivirano)
What benefit has Versican Plus DHPPi/L4 shown during the studies? 
Kakšne koristi je zdravilo Versican Plus DHPPi/L4 izkazalo med študijami?
Versican Plus DHPPi/L4 is available as a lyophilisate (freeze-dried pellet) with a solvent for injection. 
Zdravilo Versican Plus DHPPi/L4 je na voljo v obliki liofilizata (pelet, posušenih v zamrznjenem stanju) z vehiklom za injiciranje.
The viruses in Versican Plus DHPPi/L4 are alive but they have been attenuated (weakened) so that they do not cause disease; they are combined with killed (inactivated) strains of Leptospira bacteria. 
Virusi v cepivu Versican Plus DHPPi/L4 so živi, vendar so atenuirani (oslabljeni), tako da ne povzročajo bolezni.
Other information about Versican Plus DHPPi/L4: 
Druge informacije o zdravilu Versican Plus DHPPi/L4:
What is the risk associated with Versican Plus DHPPi/L4? 
Kakšna tveganja so povezana z zdravilom Versican Plus DHPPi/L4?
Why has Versican Plus DHPPi/L4 been approved? 
Zakaj je bilo zdravilo Versican Plus DHPPi/L4 odobreno?
For revaccination, a single dose of Versican Plus DHPPi/L4 is required every three years for distemper, canine adenovirus (type 1 and type 2) and parvovirus. 
Za zaščito pred pasjo kugo, pasjim adenovirusom (tipa 1 in 2) ter pasjim parvovirusom je vsaka tri leta potrebno ponovno cepljenje z enkratnim odmerkom cepiva Versican Plus DHPPi/L4.
How has Versican Plus DHPPi/L4 been studied? 
Kako je bilo zdravilo Versican Plus DHPPi/L4 raziskano?
What is Versican Plus DHPPi/L4? 
Kaj je zdravilo Versican Plus DHPPi/L4?
What is Versican Plus DHPPi/L4 used for? 
Za kaj se zdravilo Versican Plus DHPPi/L4 uporablja?
How does Versican Plus DHPPi/L4 work? 
Kako zdravilo Versican Plus DHPPi/L4 deluje?
Both groups had similar demographics. 
Obe skupini sta imeli podobne demografske značilnosti.
It's especially important to mention: 
Posebej pomembno je, da omenite:
Date of first authorisation: 22 March 2002 Date of latest renewal: 24 January 2012 
Datum prve odobritve: 22 marec 2002 Datum zadnjega podaljšanja: 24 januar 2012
You will not be given more than 80 mg in 24 hours. 
V 24 urah ne boste dobili več kot 80 mg.
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>. 
Navodilo je bilo nazadnje revidirano <{MM/LLLL}> <{mesec LLLL}>
Medicines can sometimes interfere with each other. 
Pri zdravilih lahko včasih pride do medsebojnih delovanj.
These effects are usually reversible. 
Ti učinki so običajno reverzibilni.
No formal interaction studies have been done. 
Formalnih študij o medsebojnem delovanju niso opravili.
It is to be reconstituted only with one of the following: 
Rekonstituira se ga lahko le z naslednjim:
The clinical relevance of these observations has not been established. 
Klinični pomen teh opažanj ni znan.
This medicinal product must not be mixed with other medicinal products except for those mentioned in section 6.6. 
Zdravila ni dovoljeno mešati z drugimi zdravili, razen s tistimi, ki so navedena v poglavju 6.6.
If a dose lower than 40 mg is required, excess medicine should be discarded. 
Če je potreben odmerek, manjši od 40 mg, je treba presežek zdravila zavreči.
Additional studies in other surgical settings provided similar observations. 
Dodatne študije v drugih kirurških okoliščinah so privedle do podobnih opažanj.
The solution is for single use only and must not be stored in a refrigerator or freezer. 
Raztopina je namenjena samo za enkratno uporabo in se je ne sme shranjevati v hladilniku ali zmrzovalniku.
Children and adolescents Children and adolescents under the age of 18 should not be given Dynastat. 
Otroci in mladostniki Otrokom in mladostnikom, mlajšim od 18 let, se zdravila Dynastat ne sme dajati.
The carcinogenic potential of parecoxib has not been evaluated. 
Karcinogenega potenciala parekoksiba niso ocenili.
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
Such effects may occur shortly after treatment initiation and are usually reversible. 
Taki učinki se lahko pojavijo kmalu po uvedbi zdravljenja in so običajno reverzibilni.
The physician should be prepared to treat severe hypotension. 
Zdravnik naj bo pripravljen na zdravljenje hude hipotenzije.
All patients received standard of care analgesia during treatment. 
Vsi bolniki so med zdravljenjem prejemali standardno analgezijo.
It may also play a role in ulcer healing. 
Morda igra vlogo tudi pri celjenju ulkusov.
Unless such requirements are met, in-storage times and conditions prior to use are the responsibility of the user, and would not normally be longer than 12 hours at 25C. 
Če tovrstni pogoji niso izpolnjeni, so čas shranjevanja in pogoji shranjevanja rekonstituirane raztopine pred uporabo odgovornost uporabnika; običajno naj čas ne bi bil daljši od 12 ur pri temperaturi 25 °C.
The exact magnitude of the risk associated with a single dose has not been determined, nor has the exact duration of therapy associated with increased risk. 
Natančna velikost tveganja, povezanega z uporabo enkratnega odmerka, ni bila ugotovljena, prav tako pa ni bilo ugotovljeno natančno trajanje zdravljenja, ki je povezano s povečanim tveganjem.
Your doctor may reduce the dose of Dynastat or other medicines, or you may need to take a different medicine. 
Zdravnik bo morda moral zmanjšati odmerek zdravila Dynastat ali drugih zdravil, ali pa boste morali vzeti drugačno zdravilo.
Therefore, parecoxib is not recommended in these patients. 
Parekoksiba se zato pri tej skupini bolnikov ne priporoča.
CABG post-operative safety studies 
CABG študije varnosti po operacijah
If blood pressure rises significantly, alternative treatment should be considered. 
Če krvni tlak občutno naraste, je treba razmisliti o drugih možnostih zdravljenja.
Dynastat must be reconstituted before use. 
Zdravilo Dynastat je treba pred uporabo rekonstituirati.
Dynastat is not recommended in the first 6 months of pregnancy and you must not receive Dynastat in the last three months of pregnancy. 
Zdravila Dynastat ni priporočljivo uporabljati v prvih 6 mesecih nosečnosti in zdravila Dynastat ne smete prejeti v zadnjih 3 mesecih nosečnosti.
The following solutions cannot be used for reconstitution: 
Naslednjih raztopin se za pripravo ne sme uporabljati:
The effect of enzyme induction has not been studied. 
Učinek indukcije encimov ni raziskan.
Do not use this medicine after the expiry date which is stated on the carton and on the vial label after Exp. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na nalepki viale poleg oznake »EXP«.
For the short-term treatment of postoperative pain in adults. 
Za kratkotrajno zdravljenje pooperacijske bolečine pri odraslih.
The effects of parecoxib have not been evaluated in late pregnancy or in the pre- and postnatal period. 
Učinkov parekoksiba niso ovrednotili v pozni nosečnosti in v pred- ali poporodnem obdobju.
The entire contents of the vial should be withdrawn for a single administration. 
Za enkratno uporabo je treba izvleči celotno vsebino viale.
What Dynastat is and what it is used for 
Kaj je zdravilo Dynastat in za kaj ga uporabljamo
Other medicines and Dynastat 
Druga zdravila in zdravilo Dynastat
Two isoforms, COX-1 and COX-2, have been identified. 
Znani sta dve izoobliki, COX-1 in COX-2.
Pregnant women on NSAIDs should be closely monitored for amniotic fluid volume. 
Nosečnice, ki jemljejo NSAID, je treba skrbno spremljati glede volumna amnijske tekočine.
The safety and efficacy of parecoxib in children under 18 years old have not been established. 
Varnost in učinkovitost parekoksiba pri otrocih, starih do 18 let, nista bili dokazani.
Reports from post-marketing experience have been listed as “frequency not known” because the respective frequencies cannot be estimated from the available data. 
Poročila iz izkušenj v obdobju trženja zdravila so navedena v rubriki »neznana pogostnost«, saj odgovarjajoče pogostnosti iz razpoložljivih podatkov ni mogoče oceniti.
Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis 
Stevens-Johnsonov sindrom, multiformni eritem, eksfoliativni dermatitis
Data from epidemiological studies suggest an increased risk of miscarriage after use of prostaglandin synthesis inhibitors in early pregnancy. 
Podatki iz epidemioloških študij kažejo na večje tveganje za splav po uporabi zaviralcev sinteze prostaglandinov v zgodnji nosečnosti.
About 70% of the dose is excreted in the urine as inactive metabolites. 
Približno 70 % odmerka se izloči z urinom v obliki neaktivnih presnovkov.
Dynastat will be given to you by a doctor or nurse. 
Zdravilo Dynastat vam bo dal zdravnik ali medicinska sestra.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali medicinsko sestro, preden vzamete to zdravilo.
You will only be given Dynastat for short periods, and only for pain relief. 
Zdravilo Dynastat boste dobivali le kratek čas in samo za ublažitev bolečin.
Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, Coxibs, ATC code: M01AH04 
Farmakoterapevtska skupina: zdravila s protivnetnim in protirevmatičnim učinkom, koksibi, oznaka ATC: M01AH04
What you need to know before you use Dynastat 
Kaj morate vedeti, preden boste uporabili zdravilo Dynastat
The shelf life of the unreconstituted product is 3 years. 
Rok uporabnosti nerekonstituiranega zdravila je 3 leta.
Dynastat is used for the short-term treatment of pain in adults after an operation. 
Zdravilo Dynastat se uporablja za kratkotrajno zdravljenje bolečin pri odraslih po operaciji.
Appropriate measures should be taken by physicians to monitor for any serious skin reactions with therapy, e.g. additional patient consultations. 
Zdravniki morajo izvajati ustrezne ukrepe za nadzor kakršnihkoli resnih kožnih reakcij med zdravljenjem, npr. z dodatnimi kontrolami bolnika.
Studies in types of surgery other than CABG procedures included patients with American Society of Anaesthesiology (ASA) Physical Status Class I-III only. 
Študije drugih tipov operacijskih posegov, razen postopkov CABG, so vključevale le bolnike s kliničnim statusom Ameriškega združenja za anesteziologijo (ASA - American Society of Anaesthesiology), razreda I-III.
Higher doses were associated with aggravation and delayed healing of skin infections, an effect probably associated with COX-2 inhibition. 
Večji odmerki so bili povezani s poslabšanjem in upočasnjenim zdravljenjem kožnih okužb, kar je verjetno učinek, povezan z zavrtjem COX-2.
▪ If you are breast-feeding, you must not receive Dynastat, as a small amount of Dynastat will be transferred to your breast milk. 
• Če dojite, ne smete prejeti zdravila Dynastat, ker lahko majhna količina zdravila Dynastat prehaja v vaše mleko.
Do not use Dynastat if you have severe liver disease 
Ne uporabljajte zdravila Dynastat, če imate hudo bolezen jeter.
Therefore, antiplatelet therapies should not be discontinued (see section 5.1). 
Zato antiagregacijskega zdravljenja ne smemo ukiniti (glejte poglavje 5.1).
The reconstituted product should be used immediately (up to 24 hours if prepared aseptically), and should not be frozen or refrigerated. 
Rekonstituirano zdravilo je treba uporabiti takoj (v roku 24 ur, če je bilo rekonstituirano z uporabo aseptične tehnike) in se ga ne sme zamrzovati ali shranjevati v hladilniku.
In the pooled analysis of 676 patients, 318 received placebo and 358 received parecoxib. 
V združeni analizi 676 bolnikov je 318 bolnikov dobivalo placebo, 358 bolnikov pa parekoksib.
It represents approximately 10% of the concentration of valdecoxib; because of this metabolite's low concentration, it is not expected to contribute a significant clinical effect after administration of therapeutic doses of parecoxib. 
Predstavlja približno 10 % koncentracije valdekoksiba; zaradi majhne koncentracije tega presnovka ni pričakovati, da bi imel pri uporabi terapevtskih odmerkov parekoksiba pomemben klinični učinek.
Your doctor may want to monitor your blood pressure during treatment with Dynastat. 
Vaš zdravnik bo med zdravljenjem z zdravilom Dynastat morda želel nadzirati vaš krvni tlak.
The decision to prescribe a selective cyclooxygenase-2 (COX-2) inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3 and 4.4). 
Odločitev, da se predpiše selektivni zaviralec ciklooksigenaze-2 (COX-2), mora temeljiti na oceni vseh tveganj za vsakega posameznega bolnika (glejte poglavji 4.3 in 4.4).
Most trials were designed for dosing of parecoxib up to 3 days. 
Večino preskušanj so zasnovali za do 3-dnevno odmerjanje parekoksiba.
However, inhibition of prostaglandin synthesis might adversely affect pregnancy. 
Vendar pa lahko zaviranje sinteze prostagladinov neugodno vpliva na nosečnost.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali katerokoli pomožno snov navedeno v poglavju 6.1.
Opioid analgesics can be used concurrently with parecoxib, dosing as described in the paragraph above. 
Opioidne analgetike lahko uporabljamo hkrati s parekoksibom, odmerjanje pa mora biti takšno, kot je opisano v zgornjem odstavku.
Parecoxib has been used in a range of major and minor surgeries. 
Parekoksib so uporabili pri različnih večjih in manjših kirurških posegih.